Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021 08:00 ET
|
Aprea Therapeutics
60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea...
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
December 13, 2021 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Pressmeddelande Stockholm, 11 december, 2021 Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021 Immunicum AB...
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB...
Jumio Acquiring 4Stop, Redefining the End-to-End Identity Platform
December 07, 2021 06:00 ET
|
FourStop GmbH
KOLN, Germany, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Jumio, the leading provider of AI-powered end-to-end identity orchestration, eKYC and AML solutions, today announced that the company is acquiring...
Aptose to Hold Corporate Update Monday, December 13th
November 29, 2021 07:30 ET
|
Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...
APWG Report: Phishing Smashes All Previous Records in Q3, 2021; Phishing Attacks Double Since Early 2020
November 22, 2021 08:00 ET
|
APWG
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- The APWG's new Phishing Activity Trends Report reveals that the APWG saw 260,642 phishing attacks in July 2021 - the highest monthly total...
Kyckr and Simple KYC Announce Partnership and Launch of UBO Verify
November 16, 2021 09:00 ET
|
Kyckr
SAN FRANCISCO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Kyckr Limited (ASX:KYK) (Kyckr or the Company), a B2B information services company, is pleased to announce its partnership with Simple KYC, an...
Korean Data Intelligence Trailblazer S2W Joins Membership of APWG
November 08, 2021 09:00 ET
|
APWG
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Korean cyberthreat intelligence trailblazer S2W has established a partnership with Anti-Phishing Working Group (APWG), the international...
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
November 05, 2021 09:41 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...